Stocks · News reference

DexCom shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance. Also, multiple analysts raised their respective price targets on the stock.

Jul 31, 2026, 2:59 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Zacks Investment ResearchAug 31, 2026, 12:30 PMZacks.Com
Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today
A $1,000 investment in DexCom (DXCM) made 10 years ago in August 2016 would be worth $3,981.59 as of August 31, 2026, representing a 298.16% gain. This significantly outperformed the S&P 500's 255.54% gain over the same period. DexCom, a medical device company specializing in continuous glucose monitoring systems, reported 2025 revenues of $4.66 billion (up 16% YoY) and adjusted EPS of $2.09 (up 27.4% YoY). Analysts remain optimistic about future growth despite competitive market pressures.
DXCM
BenzingaAug 26, 2026, 1:36 PMVandana Singh
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.
ABT BBNX DXCM MMED PODD
BenzingaAug 4, 2026, 2:17 PMBenzinga Newsdesk
Argus Research Maintains Buy on DexCom, Raises Price Target to $96
Argus Research analyst Steve Silver maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $86 to $96.
DXCM
BenzingaAug 3, 2026, 9:19 PMBenzinga Newsdesk
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $90
Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $82 to $90.
DXCM